NCT00534027View on ClinicalTrials.gov

A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

AMG 655

AMG 655 is a monoclonal antibody directed against TR-2.

OTHER

AMG 655 placebo

Inactive dummy AMG 655 (to maintain blind)

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY